Adaptive Biotechnologies (HAM:1HM) EPS without NRI: €-0.29 (TTM As of Mar. 2026)


HAM:1HM Adaptive Biotechnologies Corp HAM:1HM
47 GF Score
Price €18.54
GF Value €8.80
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies EPS without NRI?

Adaptive Biotechnologies HAM:1HM -6.53% 47 EPS without NRI is €-0.29 as of Mar. 2026. GuruFocus rates HAM:1HM with a GF Score™ of 47/100 and a GF Value™ of €8.80 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 161 Medical Diagnostics & Research companies, Adaptive Biotechnologies ranks better than 72.67% on this metric.

Adaptive Biotechnologies's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.11. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.29.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 34.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 16.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Adaptive Biotechnologies's EPS without NRI or its related term are showing as below:

HAM:1HM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -49.9   Med: -9.55   Max: 34.7
Current: 34.7

During the past 9 years, Adaptive Biotechnologies's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 34.70% per year. The lowest was -49.90% per year. And the median was -9.55% per year.

HAM:1HM's 3-Year EPS without NRI Growth Rate is ranked better than
72.67% of 161 companies
in the Medical Diagnostics & Research industry
Industry Median: 10.8 vs HAM:1HM: 34.70

Adaptive Biotechnologies's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.11. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.29.

Adaptive Biotechnologies's EPS (Basic) for the three months ended in Mar. 2026 was €-0.11. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.29.


Adaptive Biotechnologies  (HAM:1HM) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Adaptive Biotechnologies EPS without NRI Related Terms


Adaptive Biotechnologies EPS without NRI Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies EPS without NRI Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -1.31 -1.32 -1.27 -0.99 -0.33

Adaptive Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.15 0.05 -0.08 -0.11

HAM:1HM vs GRAL, WGS, RDNT: EPS without NRI Comparison

For the Diagnostics & Research subindustry, Adaptive Biotechnologies's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's PE Ratio without NRI falls into.


HAM:1HM
47GF Score
Adaptive Biotechnologies Corp HAM:1HM
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.29 mean?
Adaptive Biotechnologies (HAM:1HM) has a EPS without NRI of €-0.29 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Adaptive Biotechnologies and its competitors. According to the industry distribution chart, Adaptive Biotechnologies ranks #44 out of 161 companies in the Medical Diagnostics & Research industry, placing it in the top 27.3%.
Is Adaptive Biotechnologies' EPS without NRI too high?
Adaptive Biotechnologies' current EPS without NRI is €-0.29. Based on the distribution chart, Adaptive Biotechnologies ranks #44 out of 161 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Adaptive Biotechnologies has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' EPS without NRI compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #44 out of 161 companies for EPS without NRI. This puts Adaptive Biotechnologies in the upper half of its industry. The industry median EPS without NRI is 10.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.80, based on 161 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Adaptive Biotechnologies and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptive Biotechnologies's current EPS without NRI is €-0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (HAM:1HM) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.80, compared to a current price of €18.54 — trading 110.7% above its estimated fair value. The current EPS without NRI is €-0.29. Adaptive Biotechnologies' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Adaptive Biotechnologies (HAM:1HM), the current EPS without NRI is €-0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (HAM:1HM) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of €18.54 is trading 110.7% above its estimated GF Value™ of €8.80. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for HAM:1HM:

  • EPS without NRI: €-0.29
  • GF Value™: €8.80 vs. price of €18.54 (110.7% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the HAM:1HM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adaptive Biotechnologies Business Description

Other Exchanges ADPT:USA1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
47GF Score

Get the complete analysis for HAM:1HM

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.54
Price
€8.80
GF Value